<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805649</url>
  </required_header>
  <id_info>
    <org_study_id>MK-KTAMD-2008</org_study_id>
    <nct_id>NCT00805649</nct_id>
  </id_info>
  <brief_title>Combined Therapy in Age-Related Macular Degeneration (ARMD)</brief_title>
  <official_title>Combined Therapy in ARMD - Retrospective Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of combined intravitreal therapy
      with or without prior photodynamic therapy in patients with wet age-related macular
      degeneration (AMD).

      In patients with wet AMD, a significant improvement in vision was observed after combined
      intravitreal therapy with or without prior photodynamic therapy. Both the pharmacological
      effects of the drugs and the physiological effects of the pars plana vitrectomy (posterior
      vitreous detachment, liquefaction, and oxygen redistribution) may have contributed to the
      long-term sustainability of the therapeutic benefits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study of a case series included eyes with predominantly classic lesions
      (Group 1; n = 52) and eyes with occult lesions (Group 2; n = 106). Patients with
      predominantly classic lesions received low fluorescence photodynamic therapy (42 J/cm2 for 72
      sec), followed by, 24 hours later, a 1.5 mL core pars plana vitrectomy with intravitreal
      injection of dexamethasone (0.8 mg) and bevacizumab (1.25 mg). Patients with occult lesions
      received a 0.4 mL core pars plana vitrectomy with intravitreal injection of triamcinolone (8
      mg) and bevacizumab (1.25 mg). At baseline and follow-up examinations, the best-corrected
      visual acuity (BCVA; logMar), central macular thickness (optical coherence tomography),
      intraocular pressure (IOP; Goldmann tonometry) were determined. In addition, the need for
      retreatment was assessed, and adverse events were monitored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>at the day of exam</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Central macular thickness</measure>
    <time_frame>at the day of exam</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eyes with predominately classic lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eyes with occult lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Low fluorescence Photodynamic therapy</intervention_name>
    <description>42 J/cm2 for 72 sec</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>core pars plana vitrectomy</intervention_name>
    <description>24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>intravitreal injection of 0.8 mg dexamethasone</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>intravitreal injection of 1.25 mg bevacizumab</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>core pars plana vitrectomy</intervention_name>
    <description>0.4 mL core pars plana vitrectomy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcincolone</intervention_name>
    <description>intravitreal injection of 8 mg triamcincolone</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Wet age related macular degeneration

        Exclusion Criteria:

          -  Opacities in lens or cornea

          -  Ongoing intraocular inflammation

          -  Trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abteilung für Netzhaut und Glaskörperchirurgie</name>
      <address>
        <city>Frankfurt/Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>September 26, 2012</last_update_submitted>
  <last_update_submitted_qc>September 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Michael Koss</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>ARMD</keyword>
  <keyword>combined therapy</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Temazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

